India Oncology NGS Market Size, Share & Trends Analysis Report By End-use (Clinical Research, Hospitals & Clinics), By Technology, By Application, By Product & Service, By Workflow, And Segment Forecasts, 2021 - 2028

Report Overview

The India oncology NGS market size was valued at USD 16.87 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 19.6% from 2021 to 2028. The introduction of cloud-based solutions in clinical research and, hospitals and biotech entities is anticipated to ease the process of managing a wide range of NGS-generated data. In addition, initiatives taken to build a genomic database for the Indian population drive market growth. In July 2021, the National Institute of Biomedical Genomics, India built dbGENVOC. It is a database of genomic variations in oral cancer. The project is funded by the Department of Biotechnology, India, to build a powerful search engine for bioinformatics analysis. It involves large data, including approximately 24 million germline and somatic variants derived from whole-exome sequences and whole-genome sequences.

In October 2021, professionals from Clever gene stated that India holds great potential for genomics as it is a new and emerging market. Back in 2015, there were majorly 2 to 3 players, while in 2021 there are about 13 to 14 primary players in the Indian market and about 3 to 4 companies have an optimal level of capacity and infrastructure to perform Next Generation Sequencing (NGS) workflows. The key advantage is the diversity in the populations, which assists in collecting a large pool of samples. Genotypic TechnologyPvt. Ltd., a Hyderabad-based sequencing company, shared their cost of sequencing 100 samples, which is around USD 10,683.73 (INR 1 = 0.013 USD), and that accounts for USD 106.84 for one sample in 2021. However, an increase in the volume can help achieve economies of scale and deteriorate the cost further to USD 53.36 per sample. This exponential decline in the costs for genetic sequencing is a high-impact rendering driver of the market.

The COVID-19 pandemic and subsequent lockdowns have had an adverse impact on cancer care and oncology research in India. The uncertainty associated with the pandemic initiated novel risks for cancer patients as it disrupted the oncology treatment delivery as well as the continuity of research. According to multiple research publications, there was a nearly 80% drop in cancer screening appointments in March and April 2020. Even after a reduction in the use of sequencing for oncology, sequencing platforms have been used in India for the analysis of SARS-CoV-2 for analysis of viral disease.

Technology Insights

The targeted & gene panel sequencing segment dominated the market with a revenue share of74% in 2020. Targeted sequencing comprises the shortest read lengths and accounts for the largest share of the market. This is due to the high penetration rate and increasing market presence for a relatively longer duration than other sequencing technologies. Targeted sequencing panels are expected to remain the workhorse for cancer molecular diagnostics and are projected to be included in the routine diagnosis of heme malignancies and solid tumors. Private enterprises in India that offer genome mapping have also ventured into testing services that can predict the risk of diabetes and cancer. These tests may range from USD 350 to 700. However, these genetic tests do not guarantee an accurate or comprehensive prognosis for individuals. These limitations can be overcome by the development of indigenous genomic databases.

In September 2021, research was published on the changing genomic in Triple-negative breast cancers in the Indian population. The study used TruSeq Cancer Amplicon panel to sequence 51 samples of TNBC patients. The research was an effort to understand the genomic landscape of TNBCs in the Indian population. Thus, such studies will boost the need for Amplicon-based NGS panels in India. The advancements in whole genome sequencing capabilities in India are anticipated to boost this segment at a substantial rate. Other factors responsible for the growth of this segment include the establishment of the base-by-base view of the rare mutations and variants detected in the cancer tissue. Moreover, the introduction of technologically advanced systems with simplified software and analysis algorithms is expected to increase the reliability of NGS technology, and thus propel market growth.

Application Insights

The diagnostics & screening segment is expected to grow at the fastest CAGR of 20.9% from 2021 to 2028. Although NGS is extensively used for cancer research, recently, it is being used in NGS-based molecular diagnosis of cancer. This is because the technology allows simultaneous sequencing of a number of target genes and provides rich diagnostic markers that aid in the development of molecular diagnostic tests.

The use of NGS technology in cancer treatment ensures early diagnosis, which helps initiate the treatment in time. Therefore, the arrival of NGS for cancer diagnosis has opened many new frontiers in the field of diagnostics. For instance, large-scale projects, such as International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA), have already issued data from thousands of tumors across major cancer types that can be used to have a comprehensive overview of cancerous cells and help enhance the prognostic and therapeutic applications.

Currently, targeted genetic tests are used as prognostic and diagnostic tools in clinical oncology, and the development of more extensive genomic tests is expected in the near future. The implementation of NGS for the discovery of new cancer-related genes, tumor heterogeneity, and identification of alterations that contribute to tumorigenesis is expected to result in significant growth of the research studies segment.

Product & Service Insights

The platforms and related products segment accounted for the largest revenue share of 76.5% in 2020. The presence of big-data analytics healthcare startups, such as inDNA Research Labs, which is at the forefront to accelerate the use of genomics technologies in routine clinical care contributes to the revenue growth in this segment. inDNA Research Labs offers OncoNGx Genomic Workbench, a HIPAA-compliant cloud-based clinical annotation and informatics platform, which translates NGS data from a cancer testing gene panel into actionable insights for clinicians. Takara Bio, Agilent Technologies, and other global players assist the NGS analysis in India by providing consumables, such as library preparation kits and reagents, to India-based core facility NGS users. For instance, Takara Bio India Private Ltd. offers PrepX reagents for a simple, automated NGS library preparation process to accelerate the Illumina sequencing process.

MedGenome offers a wide range of library preparation kits based on the sequencing type. Furthermore, emerging new applications of NGS technology in diagnostics boost the adoption rate in this segment. For instance, the Direct-to-Consumer (DTC) genomics market has gained significant traction in developed countries, such as the U.S. In contrast, the DTC genomics market is in its nascent stages in India. With roughly four times the U.S. population, the country represents a large consumer market with significant potential for lucrative growth in the coming years. Mapmygenome, one of the first DTC genomics companies in India, leverages Illumina’s solutions to deliver several genetic tests to help consumers understand their genomes and their family’s genetic history.

Workflow Insights

NGS sequencing is the most important phase of the workflow and accounted for the largest share of 54.5% in 2020. Platforms that are widely utilized for sequencingincludeThermo Fisher Scientific’s Ion Torrent, and a few products from Illumina, including the HiSeq X series, MiSeq, MiniSeq, NovaSeq, iSeq, and NextSeq.Tertiary data analysis is the final and third step of analyzing NGS data that addresses the major issue of making meaning of the raw data. The tertiary analysis has generated the largest share of the revenue from NGS data analysis, owing to a consequence of important steps implemented in this segment. The process includes QA & QC of variant calls, population structure analysis, multi-sample processing, association analysis, exploratory analysis, data aggregation, and annotation & filtering.

The acceptance of NGS library preparation kits for tumor RNA and tumor DNA sequencing is expected to fuel the pre-sequencing segment. In addition, the presence of Lotus DNA Library Prep Kit, xGen Prism DNA Library Prep Kit by Integrated DNA Technologies, and other products in India will boost the market growth. Lotus applies enzymatic fragmentation technology that is employed to generate libraries that are appropriate for PCR-amplified, targeted, and PCR-free sequencing on Illumina platforms.

End-use Insights

The hospitals and clinics segment generated the highest revenue share of 34.4% in 2020. A report by National Cancer Registry Program stated that the Indian Council of Medical Research estimated 1.3 million cancer cases in India in 2020 and is anticipated to reach 1.57 million by 2025. Thus, the increasing number of cancer cases necessitates robust and improvised diagnostics strategies. The introduction of NGS-based cancer tests and panels in Asia has considerably addressed initial phase cancer testing issues in the hospitals and clinics in India. The availability of on-site bioinformatics courses that include training on the practical execution of NGS sequencing and data analysis are anticipated to boost the revenue-generating capability via the academic research segment.

In July 2021, the team of the Directorate of Public Health (DPH) and Preventive Medicine of India underwent the training in the next-generation sequencing in Bengaluru. The team will operate and manage the NGS facility at the DPH’s State Public Health Laboratory in Chennai. The team includes a biochemist, a doctor, a biotechnologist, and a microbiologist from DPH. The purpose of training specialists from various fields is to optimize the use of NGS data in the research of different streams. The research institutes are well-equipped with NGS platforms and solutions from major suppliers, such as Thermo Fisher and Illumina. For instance, the Genomics Core Facility (CCF) at the Rajiv Gandhi Centre for Biotechnology uses the Ion Proton system and Thermo Fisher’s Ion Personal Genome Machine System (PGM) to expand transcriptome sequencing, whole-genome sequencing (de novo and resequencing), metagenomics-based research activities, and exome sequencing.

Key Companies & Market Share Insights

The operating companies are undertaking various strategic initiatives in the field of oncology NGS, including new product development, mergers & acquisitions, and regional expansion, to strengthen their market presence and address the unmet needs of consumers. Premas Life Sciences Pvt. Ltd. is one of the major players in the market. The company is an accredited partner of Illumina in India and offers training, software, reagents, platforms, and troubleshooting services to laboratories in the field of genetic testing in the country. It also provides AmpliSeq for SARS-COV-2 Research Panel, manufactured by Illumina, for epidemiological research on the SARS-COV-2 virus in India. In addition, the company is a distributor of products from 10X genomics, Fluidigm, Unchained Labs, and other companies.

MedGenome Labs Ltd. is another key private-sector genomic solutions supplier in India. In July 2021, International Finance Corp. invested USD 16.5 million in MedGenome Labs to assist in the expansion of research and diagnostic services.  The company has also partnered with Singapore-based university, Nanyang Technological University, to sequence 1,00,000 whole genomes in the Asia Pacific region as part of the Genome Asia project. The company also provides Comprehensive Tumor Panel, C-MET amplification, and Tumor Mutation Burden next-generation sequencing panels for oncology.   Some of the key players operating in the India oncology NGS market include:

• Illumina, Inc.

• Genotypic Technology Pvt. Ltd.

• Tecan Trading AG

• SciGenom Labs Pvt. Ltd.

• Xcelris Labs Ltd.

• Eurofins Scientific

• 4baseCare

• MedGenome

• Sayre Therapeutics

• Redcliffe Lifesciences

• Partek Inc.

• Bio-Rad Laboratories

• Myriad Genetics

• Hologic, Inc. (Gen-Probe Inc.)

• Perkin Elmer, IncVela Diagnostics

• Premas Life Sciences Pvt Ltd (PLS)

India Oncology NGS Market Report Scope

Segments Covered in the Report

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the India oncology NGS market report on the basis of technology, application, product & service, workflow, and end-use:

• Technology Outlook (Revenue, USD Million, 2017 - 2028)

  • Whole Genome Sequencing

  • Whole Exome Sequencing

  • Targeted & Gene Panel Sequencing

    • Amplicon-based

    • Hybridization-based

• Application Outlook (Revenue, USD Million, 2017 - 2028)

  • Diagnostics and Screening

    • Screening

      • Sporadic Cancer

      • Inherited Cancer

    • Companion Diagnostics

    • Other Diagnostics

  • Research Studies

• Product & Service Outlook (Revenue, USD Million, 2017 - 2028)

  • Platforms and Related Products

    • Panels

    • Consumables

    • Platforms

  • Services

• Workflow Outlook (Revenue, USD Million, 2017 - 2028)

  • Pre-Sequencing

    • NGS Library Preparation Kits

    • Semi-automated Library Preparation

    • Automated Library Preparation

    • Clonal Amplification

  • Sequencing

  • NGS Data Analysis

    • NGS Primary Data Analysis

    • NGS Secondary Data Analysis

    • NGS Tertiary Data Analysis

• End-use Outlook (Revenue, USD Million, 2017 - 2028)

  • Academic Research

  • Clinical Research

  • Hospitals & Clinics

  • Pharma & Biotech Entities

  • Other users